Siegfried and Keryx Biopharmaceuticals, a Boston, Massachusetts-headquartered biopharmaceutical company, have signed a master manufacturing services and supply agreement under which Siegfried will perform certain manufacturing activities at its facilities in Saint Vulbas, France and Pennsville, New Jersey.

Under the agreement, Siegfried will manufacture and supply GMP-grade quantities of the active pharmaceutical ingredient for Keryx’s drug, Auryxia (ferric citrate), for treating two common complications of chronic kidney disease.

The agreement has an initial term ending on December 31, 2021 and will automatically renew after that for successive terms of one year each.

Source: Siegfried